Editas Medicine Inc (EDIT)
2.44
+0.07
(+2.95%)
USD |
NASDAQ |
Nov 22, 15:52
Editas Medicine Total Liabilities (Quarterly): 151.93M for Sept. 30, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 151.93M |
| June 30, 2024 | 152.79M |
| March 31, 2024 | 145.95M |
| December 31, 2023 | 150.06M |
| September 30, 2023 | 144.19M |
| June 30, 2023 | 142.04M |
| March 31, 2023 | 146.63M |
| December 31, 2022 | 153.64M |
| September 30, 2022 | 116.28M |
| June 30, 2022 | 115.42M |
| March 31, 2022 | 110.35M |
| December 31, 2021 | 123.84M |
| September 30, 2021 | 130.22M |
| June 30, 2021 | 142.52M |
| March 31, 2021 | 142.30M |
| December 31, 2020 | 179.02M |
| September 30, 2020 | 156.00M |
| June 30, 2020 | 228.71M |
| March 31, 2020 | 232.17M |
| Date | Value |
|---|---|
| December 31, 2019 | 246.45M |
| September 30, 2019 | 162.37M |
| June 30, 2019 | 162.56M |
| March 31, 2019 | 161.75M |
| December 31, 2018 | 184.22M |
| September 30, 2018 | 163.18M |
| June 30, 2018 | 162.20M |
| March 31, 2018 | 156.47M |
| December 31, 2017 | 165.18M |
| September 30, 2017 | 161.34M |
| June 30, 2017 | 183.84M |
| March 31, 2017 | 188.58M |
| December 31, 2016 | 94.58M |
| September 30, 2016 | 71.98M |
| June 30, 2016 | 62.27M |
| March 31, 2016 | 47.44M |
| December 31, 2015 | 232.48M |
| September 30, 2015 | 32.13M |
| December 31, 2014 | 27.48M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
110.35M
Minimum
Mar 2022
246.45M
Maximum
Dec 2019
155.53M
Average
146.29M
Median
Total Liabilities (Quarterly) Benchmarks
| Ionis Pharmaceuticals Inc | 2.419B |
| EyePoint Pharmaceuticals Inc | 82.18M |
| Cassava Sciences Inc | 57.11M |
| Adverum Biotechnologies Inc | 90.26M |
| Regenxbio Inc | 217.70M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 327.57M |
| Shareholders Equity (Quarterly) | 175.63M |
| Current Ratio | 3.747 |